New results for Livazo(Kyowa Hakko Kirin) in Dyslipidaemia

New results show Lival/Livazo (pitavastatin)from Kyowa Hakko Kirin is as effective as other commonly used statins at lowering low density lipoprotein cholesterol (LDL-C), with excellent tolerability. It is also effective at elevating high density lipoprotein (HDL-C) levels, reducing triglyceride levels, and appears to have less effect on glycaemic control, than some other statins. Comparisons to simvastatin in patients with dyslipidemia at high risk of coronary heart disease showed both drugs were equally effective at reducing LDL-C but pitavastatin increased HDL-C by 6.8%, compared to 4.5% in the simvastatin arm. Another study showed that pitavastatin was superior to simvastatin in terms of percentage reduction of LDL-C, at lower doses and equivalent to simvastatin in percentage reduction of LDL-C at higher-doses. Comparisons to atorvastatin showed reductions in LDL-C were not significantly different between the two. A comparison of the full range of doses of pitavastatin against the lowest doses of the best tolerated statin, pravastatin in elderly patients showed both are well tolerated but pitavastatin was statistically, significantly better than pravastatin when comparing cholesterol. Data was presented in two new papers in Eur J Prev Cardiol. see "Pitavastatin shows greater lipid lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolemia or combined dyslipidaemia." Stender S, Budinski D, Hounslow N. Eur J Prev Cardiol. 2012 Jun 8. [Epub ahead of print].see "Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia." Stender S, Budinski D, Hounslow N. Eur J Prev Cardiol. 2012 Jan 23.